Skip to search formSkip to main contentSkip to account menu

Tafamidis meglumine

Known as: D-Glucitol, 1-Deoxy-1-(Methylamino)-, 2-(3,5-Dichlorophenyl)-6-Benzoxazolecarboxylate (1:1), D-Gluco-2,3,4,5,6-Pentahydroxy-N-Methylhexan-1-Aminium 2-(3,5-Dichlorophenyl)Benzoxazole-6-Carboxylate 
A soft gelatin capsule formulation containing the meglumine salt form of tafamidis, a small molecule and pharmacological chaperone with potential… 
National Institutes of Health

Related topics

Related topics

3 relations

Narrower (1)

Fx-1006A
TAFAMIDIS MEGLUMINE 20 mg ORAL CAPSULE [Vyndaqel]tafamidis

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Patient profile with ATTR-FAP and evaluation of the safety and efficacy of tafamidis meglumine in Japan – interim analysis in post-marketing surveillance
Transthyretin familial amyloid polyneuropathy (ATTR-FAP) is a fatal hereditary amyloidosis characterized by extracellular… 
2019
2019
1169Interim analysis of data from a long-term, extension trial of tafamidis meglumine in patients with transthyretin amyloid cardiomyopathy
Transthyretin amyloid cardiomyopathy (ATTR-CM), is an underdiagnosed, fatal disease caused by the deposition of… 
2019
2019
Studie ATTR-ACT: přelom v léčbě transthyretinové srdeční amyloidózy
Ke klinicky relevantnĂ­mu postiĹženĂ­ srdce mohou vĂSst AL (light-chain) amyloidĂlza Ai transthyretinovĂĄ amyloidĂlza (ATTR… 
2018
2018
Monitoring treatment response to tafamidis by serial native T1 and extracellular volume in transthyretin amyloid cardiomyopathy
Tafamidis meglumine, a transthyretin (TTR) stabilizer, is effective in delaying the progression of neuropathy in TTR amyloidosis… 
2018
2018
Spezifisches Medikament bessert Prognose
  • de
  • MMW - Fortschritte der Medizin
  • 2018
  • Corpus ID: 195342867
Es ist ein therapeutischer Durchbruch: Patienten mit kardialer Transthyretin-Amyloidose reduzieren ihr Sterberisiko deutlich… 
2013
2013
Neurological Data Collection Protocol On Tafamidis Meglumine Treatment For Familial Amyloid Polyneuropathy: Preliminary Data On Patients Enrolled By The Italian Network
2012
2012
1382 LONG-TERM EFFECTS OF TAFAMIDIS - A NEW THERAPEUTIC OPTION FOR PATIENTS WITH TRANSTHYRETIN FAMILIAL AMYLOID POLYNEUROPATHY (TTR-FAP)
2011
2011
Vyndaqel, INN-Tafamidis
  • 2011
  • Corpus ID: 52107192
2009
2009
Spotlight focuses on protein-misfolding therapies
A new drug candidate has, for the first time, modified disease progression in patients with a rare inherited proteinmisfolding… 
2009
2009
Pfizer lured to Sweden
A new drug candidate has, for the first time, modified disease progression in patients with a rare inherited proteinmisfolding… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)